Literature DB >> 1657796

Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours.

R E Hewitt1, I H Leach, D G Powe, I M Clark, T E Cawston, D R Turner.   

Abstract

Increased collagenase activity in colorectal carcinomas has recently been shown to be associated with increased malignant potential. To determine the tissue distribution of collagenase and its specific inhibitor, tissue inhibitor of metalloproteinases (TIMP), we carried out an immunohistochemical study on colorectal carcinomas (n = 20), adenomas (n = 7) and normal mucosa (n = 6). We found increased staining for collagenase in the connective tissue stroma of carcinomas, as compared with adenomas and normal mucosa. Little evidence of epithelial cell staining for collagenase was seen in any tissue. In carcinomas, both stromal fibroblasts and collagen fibres stained strongly and stromal staining was strongest close to neoplastic glands. Vascular staining was more prominent in neoplastic than normal tissues, perhaps reflecting the increased proteolytic activity during tumour angiogenesis. The pattern of TIMP immunostaining was similar to that of collagenase, although basement membrane staining for TIMP was generally more intense. Another difference was that, unlike TIMP, staining for collagenase was often increased at the invasive edge of carcinomas, perhaps reflecting increased collagenase activity at this location.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657796     DOI: 10.1002/ijc.2910490507

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Matrix metalloproteinases in gastrointestinal cancer.

Authors:  P D Brown
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

3.  Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis.

Authors:  H Herbst; T Wege; S Milani; G Pellegrini; H D Orzechowski; W O Bechstein; P Neuhaus; A M Gressner; D Schuppan
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

4.  The architecture of cancer.

Authors:  J Waxman; H Wasan
Journal:  BMJ       Date:  1992-11-28

5.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

6.  Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan.

Authors:  Mei-Due Yang; Kuo-Cheng Lin; Meng-Chun Lu; Long-Bin Jeng; Chieh-Lun Hsiao; Te-Cheng Yueh; Chun-Kai Fu; Hsin-Ting Li; Shiou-Ting Yen; Chia-Wen Lin; Cin-Wun Wu; Su-Yi Pang; Da-Tian Bau; Fuu-Jen Tsai
Journal:  Biomedicine (Taipei)       Date:  2017-06-14

7.  Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1.

Authors:  George S Karagiannis; Aaron Berk; Apostolos Dimitromanolakis; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2013-04-18       Impact factor: 6.603

Review 8.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

9.  Localization of messenger RNA for tissue inhibitor of metalloproteinases-1 and type IV collagenases/gelatinases in monkey hepatocellular carcinomas.

Authors:  C K Lindsay; U P Thorgeirsson
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

10.  Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.

Authors:  M E Stearns
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.